Grifols (NASDAQ:GRFS) Shares Gap Down – Time to Sell?

Grifols, S.A. (NASDAQ:GRFS) gapped down prior to trading on Friday . The stock had previously closed at $7.85, but opened at $7.58. Grifols shares last traded at $7.59, with a volume of 131,977 shares traded.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Price Performance

The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The firm’s fifty day moving average price is $8.29 and its 200 day moving average price is $8.12. The stock has a market cap of $5.15 billion, a PE ratio of 7.72 and a beta of 0.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GRFS. GAMMA Investing LLC increased its holdings in shares of Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC grew its holdings in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares in the last quarter. AQR Capital Management LLC bought a new stake in Grifols in the 2nd quarter worth approximately $89,000. HighTower Advisors LLC raised its holdings in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares in the last quarter. Finally, Tidal Investments LLC bought a new position in shares of Grifols during the 3rd quarter valued at approximately $147,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.